Anzeige
Meldung des Tages: Warum Kupfer und Silber aus Nevada plötzlich wieder im Fokus stehen könnten

BeOne Medicines Aktie (ADR) News

Aktie
WKN:  A1437N ISIN:  US07725L1026 US-Symbol:  ONC Branche:  Biotechnologie Land:  Schweiz
350,00 $
+13,84 $
+4,12%
292,53 € 28.01.26
Depot/Watchlist
Marktkapitalisierung *
28,99 Mrd. €
Streubesitz
51,65%
KGV
91,18
Faktor
0.0769231
Originalaktie
CH1391448177
neu: Nachhaltigkeits-Score
20 %
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,24: MM20LU
Werbung

BeOne Medicines Aktie (ADR) News

14.08.25 - PR Newswire
Biotech Stocks Rally as Oncology Market Targets $866B by 2034
Biotech Stocks Rally as Oncology Market Targets $866B by 2034 PR Newswire
14.08.25 - PR Newswire
Biotech Stocks Rally as Oncology Market Targets $866B by 2034
Biotech Stocks Rally as Oncology Market Targets $866B by 2034 PR Newswire
14.08.25 - PR Newswire
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment PR Newswire
11.08.25 - PR Newswire
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders PR Newswire
08.08.25 - PR Newswire
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep PR Newswire
08.08.25 - PR Newswire
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange PR Newswire
05.08.25 - PR Newswire
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results PR Newswire
29.07.25 - PR Newswire
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
Biotech Underdogs Line Up for Pivotal Shots at Game-​Changing Cancer Treatments PR Newswire
29.07.25 - PR Newswire
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
Biotech Underdogs Line Up for Pivotal Shots at Game-​Changing Cancer Treatments PR Newswire
29.07.25 - PR Newswire
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
Oncolytics Biotech® to Engage FDA for Potential Registration-​Enabled Study in First-​Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End PR Newswire
23.07.25 - PR Newswire
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential PR Newswire
23.07.25 - PR Newswire
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds PR Newswire
23.07.25 - PR Newswire
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds PR Newswire
22.07.25 - PR Newswire
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules PR Newswire
16.07.25 - PR Newswire
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities PR Newswire
16.07.25 - PR Newswire
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities PR Newswire
16.07.25 - PR Newswire
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types PR Newswire
10.07.25 - PR Newswire
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up PR Newswire
10.07.25 - PR Newswire
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up PR Newswire
10.07.25 - PR Newswire
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers PR Newswire

Newssuche

Videos

newspaper
27.01.26 +6,52%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »